Maravai Lifesciences Holdings, Inc.
A maker of the raw ingredients behind mRNA vaccines and therapies, Maravai LifeSciences supplies everything from its CleanCap® capping technology to impurity-detection kits used by biopharma and diagnostics companies in roughly sixty countries through its TriLink and Cygnus brands. Formed in 2014 by Carl Hull, Eric Tardif, and the private-equity firm GTCR, it grew by buying scientifically driven companies like TriLink and Cygnus. Its CleanCap® technology was a key ingredient in the Pfizer-BioNTech COVID-19 vaccine, and its name is the northern Italian word for "miracle."
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Stuart Feldman | 13G/APassive | 2.49% | 3.67M | Aug 13, 2026 |
| JD Squared Holdings II LLC | 13G/APassive | 2.03% | 3.00M | Aug 13, 2026 |
| JD Squared Capital II LLC | 13G/APassive | 2.03% | 3.00M | Aug 13, 2026 |
| Hudson View Holdings LLC | 13G/APassive | 0.46% | 674.1K | Aug 13, 2026 |
| Hudson View Capital LLC | 13G/APassive | 0.46% | 674.1K | Aug 13, 2026 |
| Matthew Barkoff | 13G/APassive | 0.2% | 290.1K | Aug 13, 2026 |
| Joshua Wool | 13G/APassive | 0.03% | 45.0K | Aug 13, 2026 |
| Millennium Management LLC | 13GPassive | 4.7% | 6.90M | Jun 29, 2026 |
| Millennium Group Management LLC | 13GPassive | 4.7% | 6.90M | Jun 29, 2026 |
| Israel A. Englander | 13GPassive | 4.7% | 6.90M | Jun 29, 2026 |